Model Structure of Human APOBEC3G

Kun-Lin Zhang1, Bastien Mangeat2, Millan Ortiz3, Vincent Zoete2, Didier Trono2, Amalio Telenti1*, Olivier Michielin3*

1 Institute of Microbiology, University Hospital Center, University of Lausanne, Lausanne, Switzerland, 2 Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland, 3 Swiss Institute of Bioinformatics, Lausanne, Switzerland

INTRODUCTION

Primate APOBEC3G has antiretroviral activity associated with the hypermutation of viral DNA through cytosine deamination (for recent review see [1–3]). Human APOBEC3G (huAPOBEC3G) fails to restrict HIV-1 due to the degradation imposed by the HIV-1 Vif [4]. In contrast, a number of primates APOBEC3G orthologs display activity against HIV-1 [5–8]. APOBEC3G has a duplicated catalytic deaminase domain (CDA); the amino-terminal domain (N-CDA) of APOBEC3G is required for viral encapsidation but not cytosine deamination [9–11].

There is no 3-D structure solved by X-ray or NMR nor an accurate model of APOBEC3G available. APOBEC3G relates to APOBEC family and AID (activation-induced deaminase) at the sequence level. Recent comparative modeling work for APOBEC-1 and AID [12–17] led to the proposition of a secondary structure alignment between APOBEC3G and cytidine deaminase [18]. The recent publishing of the crystal structure of APOBEC2 [19] provides the template to build a reliable model structure of APOBEC3G by theoretical methods.

In the present work, we model human APOBEC3G, with particular emphasis on the N-terminal domain. Using mutant data of the N-CDA, we mapped critical residues for packaging of APOBEC3G into viral particles on the new structure model of the huAPOBEC3G N-CDA. We completed the analysis by mapping N-CDA residues that are under positive evolutionary pressure in primates APOBEC3G.

While this work was concluded, Huthoff and Malim provided a detailed molecular genetic analysis of the N-CDA region spanning amino acids residues 119 to 146 (Ref [20]). This analysis defined residues 124 to 127 as having a role in APOBEC3G packaging into HIV-1 virions, and residues 128 to 130 as crucial for the interaction with HIV-1 Vif. Our current results confirm and extend this work, and place the findings in a detailed structural model that may serve to advance rational drug design.

MATERIALS AND METHODS

Target sequence and template for structural model

The huAPOBEC3G sequence (residues 1-384; NCBI accession: NP_068594, see http://www.ncbi.nih.gov/) was defined as target sequence. The newly crystallized Human APOBEC2 dimer [19] (PDB ID 2NYT obtained from Xiaojiang S. Chen, see http://www.rcsb.org/pdb/Welcome.do) served as template.

Target-template alignment

We used the align2d function of MODELLER program (http://salilab.org/modeller/) [21–23], to align huAPOBEC3G N-CDA sequence (residues 1-194) and huAPOBEC3G C-CDA sequence (residues 195-384) to the huAPOBEC2 dimer. Additional assessment of the target-template alignment compared structurally determined (DSSP, http://bioweb.pasteur.fr/seqanal/interfaces/dssp-simple.html) [24] and predicted (PSIPRED, http://bioinf.cs.ucl.ac.uk/psipred/) [25–27] secondary structures. The alignment was analyzed and viewed by Jalview (http://www.jalview.org/) [28].

Model building, evaluation and mapping of key residues

The target-template alignment was used to build the model by satisfaction of spatial restraints. The ANOLEA program (http://swissmodel.expasy.org/anolea/) [29–31], that estimates the fold-

* To whom correspondence should be addressed. E-mail: amalio.telenti@chuv.ch (AT); olivier.michielin@unil.ch (OM)
The geometry of the active site/pseudo-active site was based on the corresponding homologous active site regions of the huAPOBEC2 template. The main interaction of anti-parallel β1-β2', between huAPOBEC3G N-CDA and C-CDA was defined by restraining segments 48-56 and 235-243 as anti-parallel β-sheet, based on the huAPOBEC2 dimer. For the chain connection between N-CDA and C-CDA, the first 20 amino acid residues of C-CDA were used as a linker and modeled ab initio using the loop routine of the MODELER program.

Generation of 100 models allowed selection of the best model candidate based on the global ANOLEA score. Final refinement of alignment of gap regions was performed by generating 100 additional models, followed by selection of the best model on the basis of the ANOLEA score. The final model was energy-minimized using the CHARMM program (http://www.charmm.org/) [32] and the CHARMM22 all atom force field [33]. The minimization consisted of 200 steps of steepest descent using a dielectric constant of 1 and the Generalized Born GB-MV2 implicit solvent model without cutoff for the solvation free energy. Model evaluation was based on ANOLEA with window 5 averaging, as described above.
### Table 1. Mutation, antiviral activity, and surface exposure of residues of the huAPOBEC3G N-CDA.

| Residue | Anti-HIV activity* | Protein expression** | Solvent Accessible Surface Area *** |
|---------|-------------------|----------------------|------------------------------------|
| G13A    | ++                | ++                   | 14.1 ± 0                           |
| F17L    | ++                | ++                   | 2.4 ± 0.3                          |
| E21L    | +++               | +++                  | 0.4 ± 0.0                          |
| S28A    | ++                | +++                  | 73.9 ± 17.3                        |
| R29A    | +++               | +++                  | 187.2 ± 0                          |
| T32A    | ++                | ++                   | 6.5 ± 0                            |
| Y37A    | +++               | +++                  | 0 ± 0                              |
| T117A   | +++               | +++                  | 16.3 ± 0.8                         |
| W90L    | 0                 | ++                   | 76.0 ± 0.2                         |
| Y91A    | 0                 | ++                   | 76.0 ± 0.2                         |
| W94L    | 0                 | ++                   | 76.0 ± 0.2                         |
| L62A    | +++               | +++                  | 50.1 ± 4.3                         |
| L66R    | +                 | +                    | 7.5 ± 0                            |
| E67Q    | 0                 | +                    | 0 ± 0                              |
| F70L    | 0                 | ++                   | 0.2 ± 0                            |
| F74L    | +                 | ++                   | 4.3 ± 0                            |
| F75Q    | +++               | +++                  | 104.9 ± 0                          |
| Y76A    | +++               | +++                  | 16.3 ± 0.8                         |
| W99L    | +++               | ND                   | 0 ± 0                              |
| Y91A    | 0                 | ++                   | 16.7 ± 0                           |
| M92A    | +++               | ND                   | 0.1 ± 0                            |
| V93A    | +++               | +++                  | 0 ± 0                              |
| W94L    | +                 | +++                  | 35.0 ± 0                           |
| P96L    | ++                | ++                   | 0 ± 0                              |
| C97S    | +                 | +                    | 15.0 ± 1.5                         |
| C100S   | +                 | +                    | 0.2 ± 0                            |
| M104A   | +++               | +++                  | 0 ± 0                              |
| F107L   | +++               | +++                  | 23.6 ± 0                           |
| L108A   | +                 | ++                   | 2.5 ± 0.6                          |
| L116A   | ++                | ++                   | 0.5 ± 0                            |
| T117A   | +++               | +++                  | 19.1 ± 0                           |
| E118A   | +                 | +                    | 0 ± 0                              |
| R122A   | 0                 | +++                  | 76.6 ± 0                           |
| L123A   | +                 | ++                   | 11.6 ± 0                           |
| Y124A   | +                 | +++                  | 36.1 ± 0.7                         |
| Y125A   | +++               | +++                  | 138.6 ± 6.4                        |
| F126L   | +++               | +++                  | 22.6 ± 0                           |
| W127L   | 0                 | +++                  | 187.3 ± 17.8                       |
| D130K/N | +++               | +++                  | 88.7 ± 2.1                         |
| Y131V   | +                 | ++                   | 2.2 ± 0                            |
| E133Q   | +++               | +++                  | 112.3 ± 4.9                        |
| L135A   | +++               | +++                  | 0 ± 0                              |
| L138A   | +                 | ++                   | 0 ± 0                              |
| M152A   | ++                | ++                   | 0 ± 0                              |
| Y154A   | +                 | +++                  | 120.7 ± 0                          |
| F157L   | +                 | +++                  | 4.4 ± 0                            |
| C160S   | ++                | +++                  | 0.2 ± 0                            |
| F164L   | ++                | ++                   | 0 ± 0                              |

Novel functional residues that abolish huAPOBEC3G antiviral activity against wild-type HIV-1 infection are highlighted bold.

0 = no activity, ++ = residual activity (<10% of wild type), +++ = modest activity (10–50%), +++ = full activity.

*Semiquantitative western blot

**Estimated by side chain+backbone. Values greater than 20 suggest that the residue is exposed at the surface.

doi:10.1371/journal.pone.0000378.t001

The CHARMM program was used to calculate the solvent accessible surface area of the final model. Additionally, using the FoldX program (http://foldx.embibe.de/) [34], in silico alanine-scanning was performed by mutating each residue and calculated the change of folding energy. Molecular surface visualization was done using Chimera (http://www.cgl.ucsf.edu/chimera/) [35,36]. The surface was color-coded according to the Poisson-Boltzmann potential calculated by the UHBD program [37].

### Mutation analysis, constructs, viral production and titration

The plasmid expressing a hemagglutinin (HA)-tagged form of APOBEC3G was a kind gift from M. Malim. A series of APOBEC3G alanine and specific mutants was constructed with the QuickChange Mutagenesis kit (Stratagene). The collection was already constituted, and it was not defined on the basis of the new structural data. HIV-1 particles were produced by transient transfection of 293T cells with Fugene (Roche) of a wild-type or of a Vif-defective HIV-1 proviral clone. Viral titers were determined in single-round infectivity assays by applying filtered supernatant from producer cells on HeLa-CD4-LTRLaZ indicator cells. Virion infectivity was derived by dividing the infectious titer by the amount of physical particles.

### Packaging assay and Western Blots

HIV-1 particles were produced by transient transfection of 293T cells with Fugene (Roche). 1 ml of virus was then spun in Eppendorf tubes at 13,000 rpm in a microfuge at 4°C for 90 minutes, without sucrose cushion. Pellets were resuspended in PBS 1% Triton, and the virion amount was measured by a standard RT assay. Normalized amount of virions were then loaded on standard Laemmli protein gels to perform Western Blots. Cell extracts were obtained through a standard RIPA extraction procedure. The HA tag was detected with the mouse hrp-coupled anti-HA 3F10 antibody (Roche). PCNA (proliferating cell nuclear antigen) was detected with the mouse Ab-1 antibody (Oncogene Science). The HIV-1 capsid was detected with the murine anti-p24 antibody produced from the AIDS Research and Reference Reagent Program #183-H12-5C.

### RESULTS

The huAPOBEC2 tetramer is composed of two outer monomers and two middle monomers. The outer and middle monomers share the same sequence but a slightly different structure in the region of residues 57-68. For an outer monomer, this region is a hairpin-loop; for a middle monomer this region is a loop with residue E60 coordinating with Zn2+ [19].

The final model has a good ANOLEA score profile (indicating reliability of the structure prediction) with a pattern comparable to the huAPOBEC3G model is shown in Fig. 1B. The structural pattern of this model is very similar to that of the huAPOBEC2 dimer. The final model has a good ANOLEA score profile (indicating reliability of the structure prediction) with a pattern comparable to that of huAPOBEC2 dimer despite the low sequence identity (27%), Supplementary Fig. S1A.
Mutation analysis and mapping of key functional residues

Mutation analysis interrogated 48 of 194 (25%) residues of the huAPOBEC3G N-CDA (Table 1). Mutation of the conserved residues constituting the N-CDA Zn\(^{2+}\) coordination domain H65, C97 and C100 prevented or reduced encapsidation as previously reported [9]. Mutation of residues F70 and Y91, shown to mediate RNA binding [38], was associated with reduced APOBEC3G encapsidation, as previously reported [9]. Mutation of the pseudo-catalytic site residue E67 (E67Q), resulted in poor protein expression, which limited functional evaluation; E67A was previously reported to reduce the rates of APOBEC3G encapsidation into HIV1 virions [9]. E67 and F70 are buried inside of the model; E67A and F70A may affect folding stability (in silico alanine-scanning). Y91 is a partially exposed at the surface.

Amino acids substitutions at positions Y13, F17, F21, R29, T32, Y37, K40, S45, I49, L62, E65, Y86, W90, I92, S93, P96, M104, F107, L108, L116, T117, I118, L123, Y125, F126, D130, Y131, E133, L135, L138, M152, C160 and F164 did not result in changes in anti-viral activity. Mutations S28A, F74L, W94L, Y124A, Y154A resulted in reduced inhibition of \( \alpha \)Vif HIV-1 particles [Fig. 2]. R122, W127 and D128 form a cluster at the surface [Fig. 3] and contribute to changes in surface charge or structure [Fig. 4].

Prior evolutionary analysis of primate APOBEC3G identified a number of residues under diversifying (positive) selection [39]. Most of the residues under positive selection pressure are exposed at the surface of the model. A cluster of residues under positive selection that includes T98, K99, R102, D128, and P129 overlaps with the cluster of functionally important residues around D128 (Fig. 3).

**DISCUSSION**

This work presents a model structure of huAPOBEC3G that captures information from the recently published APOBEC2 structure [19]. Critically, the APOBEC2 template provides a structural reference for the predicted extra helix \( \alpha \)4, that carries residue D128—a residue that governs the virus-specific sensitivity of APOBEC3G to Vif-mediated inhibition [5–8]. Previously available CDA structures provided suboptimal templates for APOBEC3G N-CDA. This is not only due to the low sequence identity,
but also because of the presence in APOBEC3G N-CDA of an extra \( \alpha \) helix. In contrast, APOBEC2 has an extra \( \alpha \) helix, resulting in a \( \alpha_1-\beta_1-\alpha_2-\beta_2-\alpha_3-\beta_3-\alpha_4-\beta_4-\alpha_5 \) configuration, while CDA structures such as human cytidine deaminase have the pattern \( \alpha_1-\beta_1-\alpha_2-\beta_2-\alpha_3-\beta_3-\alpha_4-\beta_5-\alpha_5 \). In addition, the direction of \( \beta_4 \) and \( \beta_5 \) are different: parallel in APOBEC2 but antiparallel in cytidine deaminase. We had previously used the yeast Cytosine deaminase (PDB ID 1P6O, chain A) to address the position of the extra helix and the correct direction of \( \beta_4 \) and \( \beta_5 \).

The model emerging from this analysis allows speculation on various functionally relevant structural details of interest for the understanding of the Vif-APOBEC3G interaction and the process of APOBEC3G encapsidation into HIV-1 virions. In contrast with previous secondary and tertiary structure models, the current model locates the distinctive extra alpha helix on the same planar surface as the pseudo-active site. We evaluated extensive mutation data on this surface, that characterized two functionally relevant residues R122 and W127 that resulted in failure to inhibit infection by HIV-1/Δvif due to lack of packaging of APOBEC3G into viral particles. Interaction of APOBEC3G with the NC-domain of HIV-1 Gag and non-specific RNA binding leads to its encapsidation into progeny virions [10,40–43]. The structural model proposes a surface hot-spot domain that includes residues R122, W127 in proximity to the active site, and overlapping with a cluster of residues under positive selective pressure that includes D128 and P129.

Figure 3. Mapping of functional and evolutionary informative residues at the molecular surface of N-CDA. Panel A, Mapping of functional residues. The color gradient (dark red > red > orange > yellow) reflects the role of various mutations in abolishing anti-HIV activity (see Table 1) ranging from no antiviral activity (dark red) to normal activity (yellow), Panel B. Mapping of evolutionary informative residues at the molecular surface. Green color identifies amino acids under positive selective pressure in primate APOBEC3G. The positive selection cluster includes T98, K99, R102, D128, and P129. Blue color identifies the pseudo-active site.

doi:10.1371/journal.pone.0000378.g003

APOBEC3G Structure
Our results are consistent with the work of Huthoff and Malim [20]. While their work concentrated on the molecular genetic analysis of the 28-amino acid region between residues 119 and 146, our analysis interrogated 48 of the 194 residues of the N-CDA domain. This reflects the interest to identify additional motifs capable of interacting with HIV-1 Vif, or participating in packaging [20,44]. Minor differences were observed between the two studies. We observed a defect in the packaging efficiency of R122A mutant protein—that extends the relevant motif to include R122-Y124-Y125-F126-W127. Regarding the motif affecting regulation by Vif, our analysis of D130 mutants (D130K and D130N) did not result in a Vif-resistant phenotype. This difference may reflect a greater dependence of the N-CDA and Vif for the negative charge in position 128 (Ref [20]). While not formally tested in the present study, the biological relevance of P129 is highlighted by its inclusion—together with D128—in a patch of residues under positive selective pressure in primates.

Inspection of surface modifications conferred by various mutations highlights the structural and/or charge differences in this region as the molecular basis for disruption of the APOBEC3G packaging into HIV-1 virions, and modification in the interaction with Vif. The detailed model structure presented here could serve to advance rational drug design. The quality of a homology model is strongly related to the sequence identity with the structural template. The current model, based on a sequence identity of 27%, should be satisfactory in its global fold, as supported by the good ANOLEA energy score profile (Supplementary Fig. S1). From such a model, correct positioning of the protein backbone and orientation of the side chains can be expected, allowing reliable conclusion to be made in the design and interpretation of experimental mutation data. Whether or not the accuracy of such a model is sufficient to perform docking simulations is still an open question. However, the fact that critical residues obtained experimentally by mutation analysis do cluster in well-defined patches at the surface of the model argue that side chain packing is correct. In the latter case, docking simulations could be envisioned based on the current model. As recently shown for TRIM5α [45], the model proposed may serve to guide further functional analysis of APOBEC3G.

**SUPPORTING INFORMATION**

Figure S1  Panel A, Target-template alignment. Alpha helix are shown in red and beta sheets in green. The huAPOBEC3G N-CDA is aligned to the outer (O) monomer of APOBEC2, and the C-CDA to the middle (M) monomer. Panel B, ANOLEA scores. The three ANOLEA profiles and the secondary structure were aligned according to the target-template alignment. The ANOLEA profile excludes the uncharacterized linker (residues 195-214) Found at: doi:10.1371/journal.pone.0000378.s001 (2.86 MB EPS)

**ACKNOWLEDGMENTS**

We thank X.S. Chen for APOBEC2 PDB data.

**Author Contributions**

Conceived and designed the experiments: AT DT OM. Performed the experiments: KZ BM. Analyzed the data: AT DT MO KZ BM OM. Contributed reagents/materials/analysis tools: VZ OM. Wrote the paper: AT KZ OM.
REFERENCES

1. Cullen BR (2006) Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol 80: 1067–1076.
2. Yu X-F (2006) Innate cellular defenses of APOBEC3 cytidine deaminases and viral counter-defenses. Curr Opin HIV/AIDS 1: 187–193.
3. Harris RS, Matsuo H (2006) Dancin’ deaminase. Nat Struct Mol Biol 13: 380–381.
4. Sherry AM, Gadhvi NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 666–650.
5. Mangat B, Turelli P, Liao S, Trono D (2004) A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem 279: 14481–14483.
6. Bogerd HP, Dohle BP, Wiegand HL, Cullen BR (2004) A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 vif infectivity factor. Proc Natl Acad Sci U S A 101: 3562–3567.
7. Schroeder B, Chen D, Landau NR (2004) A single amino acid of APOBEC3G controls its species-specific interaction with vif infectivity factor Vif. Proc Natl Acad Sci U S A 101: 3927–3932.
8. Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, et al. (2004) A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 vif infection and vif-induced depletion. Proc Natl Acad Sci U S A 101: 6562–6567.
9. Navarro F, Bollman B, Chen H, Konig R, Yu Q, et al. (2005) Complementary function of the two catalytic domains of APOBEC3G. Virology 333: 374–386.
10. Luo K, Liu B, Xiao Z, Yu Y, Yu X, et al. (2004) Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol 78: 11841–11852.
11. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, et al. (2005) Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 15: 166–170.
12. Scott J, Navaratnam N, Carter C (1998) Molecular modelling and the biosynthesis of apolipoprotein B containing lipoproteins. Atherosclerosis 141 Suppl 1: S17–S24.
13. Navaratnam N, Fujimoto T, Bayliss J, Jarmuz A, How A, et al. (1998) Escherichia coli cytidine deaminase provides a molecular model for ApoB RNA editing and a mechanism for RNA substrate recognition. J Mol Biol 275: 695–714.
14. Xie K, Sowden MP, Dance GS, Torelli AT, Smith HC, et al. (2004) The structure of a yeast RNA-editing deaminase provides insight into the fold and function of activation-induced deaminase and APOBEC-1. Proc Natl Acad Sci U S A 101: 4114–4119.
15. Zaim J, Kieczak AM (2003) Domain organization of activation-induced cytidine deaminase. Nat Immunol 4: 1133.
16. Ta VT, Nagaoa H, Catalon N, Durandy A, Fischer A, et al. (2003) AID mutant analyses indicate requirement for class-switch-specific cofactors. Nat Immunol 4: 1145–1148.
17. Weekes JE, Dance GS, Sowden MP, Smith HC (2003) Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet 19: 207–216.
18. Huthoff H, Malim MH (2005) Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins. Virology 343: 147–153.
19. Prochnow C, Branstreitter R, Klein MG, Goodman MF, Chen XS (2006) The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature.
20. Huthoff H, Malim MH (2007) Identification of amino acid residues in APOBEC3G required for regulation by HIV-1 Vif and virion encapsidation. J Virol PMID. pp 17267497.
21. Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234: 779–815.
22. Marty-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, et al. (2000) Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 29: 291–325.
23. Fiser A, Do RK, Sali A (2000) Modeling of loops in protein structures. Protein Sci 9: 1753–1773.
24. Kabach W, Sander C (1983) Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Bioinformatics 22: 2577–2587.
25. McGuffin LJ, Bryson K, Jones DT (2000) The PSIPRED protein structure prediction server. Bioinformatics 16: 494–495.
26. Fry S, McGuffin LJ, Marsden RL, Ward JJ, Sodhi JS, et al. (2005) Protein structure prediction servers at University College London. Nucleic Acids Res 33: W36–W43.
27. Jones DT (1999) Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol 292: 195–202.
28. Clamp M, Cuff J, Searle SM, Barton GJ (2004) The Jalview Java alignment editor. Bioinformatics 20: 426–427.
29. Melo F, Feytmans E (1998) Assessing protein structures with a non-local atomic interaction energy. J Mol Biol 277: 1141–1152.
30. Melo F, Feytmans E (1997) Novel knowledge-based mean force potential at atomic level. J Mol Biol 267: 207–222.
31. Melo F, Devos D, Depierres E, Feytmans E (1997) ANOLEA: a web server to assess protein structures. Proc Int Conf Intell Syst Mol Biol 3: 187–190.
32. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, et al. (1983) CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J Comp Chem 4: 187–217.
33. MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, et al. (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102: 3586–3616.
34. Guerin R, Nielsen JE, Serrano L (2002) Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol 320: 369–387.
35. Samner MF, Olson AJ, Specht JC (1996) Reduced surface: an efficient way to compute molecular surfaces. Biopolymers 38: 305–320.
36. Peterson EF, Goddard TD, Huang CG, Couch GS, Greenblatt DM, et al. (2004) UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25: 1605–1612.
37. Davis ME, Madura JD, Luty BA, McCammon JA (1991) Electrostatics and diffusion of molecules in solution: simulations with the University of Houston Brownian Dynamics program. Comp Phys COMM 62: 187–197.
38. Navaratnam N, Bhattacharya S, Fujimoto T, Patel D, Jarmuz A, et al. (1995) Evolutionary origins of apoB mRNA editing: catalysis by a cytidine deaminase that has acquired a novel RNA-binding motif at its active site. Cell 81: 187–195.
39. Ortiz M, Bleiber G, Martinez R, Kaessmann H, Teleni A (2006) Patterns of evolution of host proteins involved in retroviral pathogenesis. Retrovirology 3: 11.
40. Cen S, Guo F, Niu M, Saadatmand J, Defaisseaux J, et al. (2004) The Interaction between HIV-1 Gag and APOBEC3G. J Biol Chem 279: 33177–33184.
41. Schafer A, Bogerd HP, Cullen BR (2004) Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328: 163–168.
42. Svarovskaia ES, Xu H, Mboya JL, Barr R, Gorelick RJ, et al. (2004) Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem 279: 35022–35028.
43. Zennou V, Perez-Caballero D, Gottlinger H, Bieniasz PD (2004) APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J Virol 78: 12059–12061.
44. Conticello SG, Harris RS, Neuberger MS (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 13: 2009–2013.
45. Ohkura S, Yap MW, Sheldon T, Stoy JP (2006) All three variable regions of the primate species-specific APOBEC3F Vif. J Virol 80: 8534–8535.